Health Check: Immuron shares bust out for a ‘run’ on strong Travelan sales

Immuron shares this morning surged more than 30% after the company reported robust sales of its traveller’s trots prophylactic, Travelan.

Conveniently for shareholders, Immuron is hot to trot because of higher Travelan sales. Pic: Getty Images

• Immuron shares surge more than 30% on robust sales of the company’s traveller’s trots prophylactic

• Visionflex turns cash flow positive

• In Tetra-theory, this one’s worth a lot more

Wake up folks! It’s mid-July but there’s still only a trickle of June quarter reports emanating from the life sciences sector.

We blame the school holidays.

In the meantime companies prefer informal, unaudited updates.

In this vein, Immuron (ASX:IMC) reports Travelan sales of $7.3 million for the year to June 2025, 49% higher.

June quarter sales came in at $2 million, up 55%,

Based on the goodness of cow’s milk, Travelan is an over-the-counter immune supplement targeting gastrointestinal pathogens.

Unlike most traveller’s diarrhoea aids, it tackles the root of the problem rather than merely bunging it up.

Travelan has been around for two decades, but the brand got a bit tired and management decided it was time to bolster promotion.

In Australia, a “clear pharmacy visibility program” helped to boost sales to $5.2 million, 40% higher.

North American sales grew 76% to $2 million, with strong Amazon sales driving demand.

Meanwhile medical pot supplier Little Green Pharma (ASX:LGP) reports June quarter revenue of $9.1 million, up 20%, and receipts of $12 million (50% higher).

Little Green also has positive cash flow of $500,000, taking the cash balance to $2.5 million.

Earlier, Little Green disclosed revenue of $36.8 million for the year to March 2025, with a $3.3 million net profit.

A Visionflex turnaround is more than a remote prospect

In news from the boondocks, remote healthcare outfit Visionflex (ASX:VFX) reports a June quarter revenue surge on the back of new contracts, while also turning cash flow positive.

Relative to the March quarter, revenue grew 148% to $2 million. On a year-on-year basis, the turnover was 14% higher.

The company managed cash flow of $300,000, compared with a $900,000 of March quarter outflows.

Visionflex provides proprietary software and hardware – such as examination cameras – to remotely diagnose patients, typically in far-flung communities.

During the quarter, Visionflex inked a $1 million deal with the Medibank Private (ASX:MPL) owned Amplar Health.

A homecare provider, Amplar operates 30 sites.

It also signed up a “leading ASX mining company” to roll out the gear across 13 medical centres and one aircraft.

Visionflex says 19% of its revenue is now recurring, which “aligns with the company’s focus on growing a more predictable, higher margin revenue base.”

This quarter, the company hopes to launch a tailored homecare product.

Given 900 providers service this sector with more than 2300 services, the company reckons it’s tapping a rich vein.

Trivarx says its depression trial is fully enrolled …

TrivarX (ASX:TRI) says it has enrolled ten patients in its veterans’ mental health trial and is on track to achieve its target of 30 participants.

A mental health technology company, TrivarX pioneers the use of objective measures to screen for mental health conditions and detect them early.

The study deploys electrocardiogram (ECG) screening to detect current major depressive episodes in veterans with suspected sleep apnoea.

The  trial is underway at the West Los Angeles VA Medical Center.

There, participants undergo an overnight, multi-parameter sleep study and neuropsychiatric interview.

The ECG algorithm extends Trivarx’s lead asset, its AI-driven MEB-001 device.

Trivarx expects to complete the study by mid-September.

... while Clarity also puts out the ‘full house’ shingle

In other trial news, radiopharmaceutical developer Clarity Pharmaceuticals (ASX:CU6) says a 50 patient, phase II study of its prostate cancer imaging candidate is fully enrolled.

The study evaluates Clarity’s copper-isotope based agent 64Cu-SAR-bisPSMA, compared to the standard-of-care gallium-based alternative.

In nuclear medicine, there are isotopes and isotopes ...

Carried out at Sydney’s St Vincent’s Hospital, the investigator-initiated study enrols patients with low prostate-specific antigen (PSA).

These patients are candidates for "curative salvage therapies".

“The high volume of patients imaged in recent months at a single site reflects the high unmet need for more effective diagnostic tools for men with rising PSA following radical prostatectomy,” Clarity executive chair Dr Alan Taylor says.

The company expects trial results “in coming months”.

Tetratherix shares ‘worth 58% more’

Tetratherix (ASX:TTX) shares have surged a healthy 22% since the wound management company listed on June 30, but broker Morgans reckons there’s another 58% of upside.

The company has developed Tetramatrix, a fluid-like polymer injected into the relevant bodily area.

The body temperature results in the material setting to a gum-like state that surgeons can shape to suit the purpose.

The material doesn’t spark a foreign body response and is reabsorbed when it has done its job.

Tetratherix initially is focusing on bone regeneration, tissue spacing, and tissue healing – a US$6.8 billion market.

The company expects FDA clearance for the dental product in late 2026, while the orthopedic and oncology spacing offerings should be green lit in late 2028.

Morgans believes the company will be profitable in the 2027-28 year but expects a current year deficit of $10.8 million on revenue of $1 million.

Morgans values the stock at $5.72 – almost double the $2.88 issue price in the $25 million raising. The firm was a joint manager for the IPO.

Pacific Edge rattles the can

Meanwhile, diagnostics house Pacific Edge (ASX:PEB) has launched a share purchase plan to raise up to NZ$5 million.

This follows the company’s June 3 conditional placement of NZ$16.1 million, NZ$1.1 million more than planned.

The raising has been done at 10 NZ cents a share, an unusual 22% premium to the prevailing price.

In April the company’s Cxbladder test was kicked off the US Medicare coverage rota.

The company says the funds partly will support operations for another 12 months without Medicare coverage, while management pursues reinstatement.

Originally published as Health Check: Immuron shares bust out for a ‘run’ on strong Travelan sales